Showing results (201-210 of 258) with videos related to

Sort By:
Pageof 26
Haematologica|June 3, 2017
Incidence of second primary malignancies and related mortality in patients with imatinib-treated chronic myeloid leukemiaGabriele Gugliotta, Fausto Castagnetti, Massimo Breccia, et al.
Blood Advances|June 11, 2026
A dynamic prognostic model for Polycythemia Vera long-terms outcomes in patients treated with RuxolitinibFrancesca Palandri, Alessandra Dedola, Giovanni Caocci, et al.
Ecancermedicalscience|June 17, 2014
Report on the international colloquium on cardio-oncology (rome, 12-14 march 2014)Michael Ewer, Luca Gianni, Fabrizio Pane, et al.
American Journal of Hematology|March 15, 2016
Rotation of nilotinib and imatinib for first-line treatment of chronic phase chronic myeloid leukemiaGabriele Gugliotta, Fausto Castagnetti, Massimo Breccia, et al.
European Journal of Haematology|November 6, 2025
Brentuximab Vedotin With Adriamycin, Vinblastine, and Dacarbazine for Patients Aged 18-59 Years With Untreated Advanced Stage Classical Hodgkin Lymphoma: The Largest Real-Life Series From Southern Italy Cancer CentersMarco Picardi, Annamaria Vincenzi, Claudia Giordano, et al.
American Journal of Hematology|May 4, 2017
The BCR-ABL1 transcript type influences response and outcome in Philadelphia chromosome-positive chronic myeloid leukemia patients treated frontline with imatinibFausto Castagnetti, Gabriele Gugliotta, Massimo Breccia, et al.
Annals of Hematology|January 20, 2025
Impact of calreticulin mutations on treatment and survival outcomes in myelofibrosis during ruxolitinib therapyFrancesca Palandri, Filippo Branzanti, Erika Morsia, et al.
Leukemia|November 18, 2025
Nilotinib versus imatinib with early switch from imatinib to nilotinib to obtain treatment-free remission in newly diagnosed chronic myeloid leukemia patients: the analysis of the first co-primary endpointFausto Castagnetti, Massimo Breccia, Elisabetta Abruzzese, et al.
Blood|January 15, 2005
A comprehensive genetic classification of adult acute lymphoblastic leukemia (ALL): analysis of the GIMEMA 0496 protocolMarco Mancini, Daniela Scappaticci, Giuseppe Cimino, et al.
Blood|May 25, 2006
Immunohistochemistry predicts nucleophosmin (NPM) mutations in acute myeloid leukemiaBrunangelo Falini, Maria Paola Martelli, Niccolò Bolli, et al.
Pageof 26